BC Extra | Dec 21, 2019
Company News

Dec. 20 Company Quick Takes: Genmab partners with CureVac; plus pair of Biogen deals, Ionis, Akcea-Novartis, Paratek and J&J-Taris

CureVac, Genmab to develop RNA-encoded antibody  Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and CureVac AG have partnered to discover an mRNA-encoded antibody candidate to treat cancer. Genmab will pay $10 million up front and invest €20 million...
BC Week In Review | Nov 30, 2017
Company News

Catalyst, Mosaic partner to develop anti-C3 proteases for dry AMD

Catalyst Biosciences Inc. (NASDAQ:CBIO) partnered with Mosaic Biosciences Inc. (Boulder, Colo.) to develop Catalyst’s preclinical anti-complement 3 (C3) proteases, including CB 2782, to treat dry age-related macular degeneration (AMD) and other inflammatory and retinal disorders....
BC Week In Review | Sep 19, 2016
Company News

Catalyst Biosciences hematology news

Catalyst will reduce headcount by 10 (50%) to about 10 to focus resources on its hemostasis programs, primarily CB 813d and CB 2679d ( ISU 304 ). The company said it will continue to explore licensing...
Items per page:
1 - 3 of 3